Summary

• The government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare.
• The MHRA will develop a more lifecycle based approach to AI medical device regulation and guidance for product changes.
• AI Airlock Phase 3 will examine post-market surveillance using real AI enabled medical devices and prototypes.

The UK government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare, moving the policy from a September blueprint into an implementation programme covering guidance, post-market oversight and possible changes to regulation.

The response published on 6 October commits the Medicines and Healthcare products Regulatory Agency and other bodies to developing a more proportionate, lifecycle based framework for AI enabled medical devices rather than relying too heavily on one assessment before a product enters service.

The recommendations themselves are not new. They were published on 10 September and Techopia covered their proposed shift towards lifecycle oversight at the time. The new development is that ministers have accepted the package in full and begun attaching actions, organisations and timetables to it.

Alongside the response, the MHRA has opened the third phase of its AI Airlock regulatory sandbox. Post-market surveillance is a central theme, allowing the regulator to test how oversight can account for the way AI enabled devices perform and change after deployment in real healthcare environments.

Implementation begins with the lifecycle

AI complicates the conventional idea that a medical device can be understood largely at the point when it is authorised. Software may be updated after launch, while its performance can also be affected by local data, workflow changes, patient populations and the way clinicians interact with it.

The Commission’s recommendations argue for stronger monitoring across that lifecycle, and the government has accepted that direction. The MHRA will build on existing post-market requirements with a more tailored set of mechanisms and consider whether legislative reform is needed to support them.

Phase 3 of AI Airlock gives the regulator a controlled environment in which to explore those questions. Applicants can bring AI enabled medical devices or prototypes into the sandbox while the MHRA examines issues including post-market surveillance, deployment context and the evidence needed to maintain assurance after introduction.

The government is also taking forward work around changes made to AI medical devices. Predetermined change control plans can give manufacturers a route to specify anticipated modifications and the controls surrounding them rather than treating every foreseeable update as though an entirely new product has appeared.

Clearer rules around qualification and classification are part of the programme as well. The response accepts recommendations intended to reduce uncertainty for developers over whether a product falls within medical device regulation and which regulatory pathway should apply.

Approval becomes one stage in a longer process

Staged authorisation remains another area for development. The Commission proposed pathways allowing some technologies to enter controlled use while additional evidence is generated, addressing limitations in a single point in time assessment of software whose performance may depend heavily on real world deployment.

The government has accepted the principle, but detailed eligibility criteria, safeguards and legal mechanisms still have to be worked out. Acceptance of a recommendation should therefore not be confused with a completed regulatory route already available to developers.

Healthcare providers will carry part of the implementation burden. Effective post-market monitoring depends on information generated inside hospitals, clinics and other care settings, including evidence about how a system performs with different patients and how staff use it in practice.

That creates a governance problem extending beyond the manufacturer. Responsibilities for deployment, monitoring, reporting and intervention need to be sufficiently clear that a deteriorating system does not sit between several organisations with each assuming another party is responsible.

The government’s supporting material promises clearer responsibilities before AI is introduced and better tools for organisations managing it after deployment. Patients are also meant to receive clearer information about where AI is being used and better routes to raise concerns when something goes wrong.

Developers gain greater regulatory predictability in return for a longer evidence obligation. A lifecycle model can reduce uncertainty around updates and deployment, but it also means safety evidence does not stop being relevant once market access has been achieved.

NICE and other organisations involved in healthcare evaluation also feature in the wider programme because regulatory evidence and adoption evidence currently serve related but different purposes. Better alignment could reduce duplicated work while preserving the distinction between proving a device is sufficiently safe and establishing that it delivers useful clinical or economic value.

Several parts of the framework still require consultation, guidance or potentially new law. The government response therefore starts the redesign rather than completing it, and further detail is expected as regulators translate each recommendation into practical requirements.

The significance of the 6 October announcement lies in that shift from recommendation to delivery. The Commission has already made the case for lifecycle regulation; ministers have now accepted it and given the MHRA a live sandbox in which to test some of the hardest implementation questions.

Healthcare AI regulation is consequently moving into a phase where operational details matter more than broad principles. Guidance on product changes, post-market evidence, responsibilities and authorisation routes will determine whether the framework can accommodate software that evolves after deployment without weakening the protections expected of a medical device regime.